Literature DB >> 6183286

Characterization of the cytosol androgen receptor of the human prostate.

D M Wilbert, J E Griffin, J D Wilson.   

Abstract

Direct measurement of the binding of endogenous androgens to the androgen receptor of human tissues has not been possible because of contamination of tissue with traces of plasma proteins, such as testosterone-binding globulin (TeBG), that contain more androgen-binding capacity than does the receptor itself. Molybdate is known to stabilize the 8-9S forms of other steroid hormone receptors. We took advantage of this phenomenon to characterize the androgen receptor of hyperplastic prostates removed at surgery, using sucrose density gradient centrifugation in a vertical rotor. In 10 mM sodium molybdate, the androgen receptor sediments as a distinct 9.2 +/- 0.5S moiety, easily separable from TeBG. Unlike TeBG, the 9S receptor is not removed by absorption with Concanavalin A. [3H]Dihydrotestosterone (3H-labeled 17 beta-hydroxy-5-alpha-androstan-3-one) binding to the 9S receptor is not removed by absorption with Concanavalin A. [3H]Dihydrotestosterone (3H-labeled 17 beta-hydroxy-5 alpha-androstan-3-one) binding to the 9S receptor is not competed for by excess triamcinolone acetonide (9 alpha-fluoro-11 beta, 16 alpha, 17 alpha, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetonide) or promegestone (17,21-dimethyl-19-non-pregna-4,9-diene-3,-20-dione), which are known to bind to the progestin receptor. In contrast, [3H]methyltrienolone (3H-labeled 17 beta-hydroxy-17 alpha-methyl-estra-4,9,11-trien-3-one) binds to both androgen and progestin receptors, and consequently, the binding of this ligand to the androgen receptor was assessed in the presence of a 500-fold excess of triamcinolone acetonide. The amounts of 9S binding (7.8 and 5.8 fmol/mg protein) are similar for dihydrotestosterone and methyltrienolone. The amount of 9S binding of testosterone to the receptor was also similar to that of dihydrotestosterone, but the affinity of testosterone for the 9S receptor was only a fifth or less of that for dihydrotestosterone. The observation that testosterone binds less avidly than dihydrotestosterone to the receptor may explain the role of dihydrotestosterone formation in androgen physiology.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6183286     DOI: 10.1210/jcem-56-1-113

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

Review 2.  Review of assessment of total androgen blockade as treatment of metastatic prostate cancer.

Authors:  J Geller
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

Review 3.  Molecular determinants of sexual differentiation.

Authors:  J S Wiener; M Marcelli; D J Lamb
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

4.  Association of V89L SRD5A2 polymorphism with craving and serum leptin levels in male alcohol addicts.

Authors:  Bernd Lenz; Eva Schöpp; Christian P Müller; Stefan Bleich; Thomas Hillemacher; Johannes Kornhuber
Journal:  Psychopharmacology (Berl)       Date:  2012-06-17       Impact factor: 4.530

5.  Inhibition of androgen receptor binding by natural and synthetic steroids in cultured human genital skin fibroblasts.

Authors:  M Breiner; G Romalo; H U Schweikert
Journal:  Klin Wochenschr       Date:  1986-08-15

6.  Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors.

Authors:  Laura J Mosher; Sean C Godar; Marc Morissette; Kenneth M McFarlin; Simona Scheggi; Carla Gambarana; Stephen C Fowler; Thérèse Di Paolo; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2018-02-16       Impact factor: 4.905

7.  Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH).

Authors:  J Geller; J Albert
Journal:  Urol Res       Date:  1987

8.  A mutation that causes lability of the androgen receptor under conditions that normally promote transformation to the DNA-binding state.

Authors:  W J Kovacs; J E Griffin; D D Weaver; B R Carlson; J D Wilson
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

9.  Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.

Authors:  Aruna V Sarma; Rodney L Dunn; Leslie A Lange; Anna Ray; Yunfei Wang; Ethan M Lange; Kathleen A Cooney
Journal:  Prostate       Date:  2008-02-15       Impact factor: 4.104

10.  High dose androgen therapy in male pseudohermaphroditism due to 5 alpha-reductase deficiency and disorders of the androgen receptor.

Authors:  P Price; J A Wass; J E Griffin; M Leshin; M O Savage; D M Large; D E Bu'Lock; D C Anderson; J D Wilson; G M Besser
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.